Adaptive Biotechnologies and Microsoft are expanding their existing partnership to map adaptive immune responses to COVID-19. Adaptive opened enrollment to collect blood samples from individuals diagnosed with or recovered from COVID-19. It also invited institutions and research groups around the world to contribute blood samples to this study. The study will involve Microsoft’s machine learning capabilities and the Azure cloud platform. The data will be made freely available through an open data portal.